Trial Profile
Safety, PK/PD and efficacy of NOX-H94 in dialysis patients with ESA-hyporesponsive anaemia: A randomized, double blind, placebo controlled parallel group study with a single blind cross-over group
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Lexaptepid pegol (Primary)
- Indications Anaemia
- Focus Adverse reactions; Proof of concept
- Sponsors NOXXON Pharma AG
- 23 Nov 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 05 Oct 2015 Planned End Date changed from 1 Aug 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.
- 05 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov.